Antibodies expand the scope of angiotensin receptor pharmacology-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antibodies expand the scope of angiotensin receptor pharmacology

Published:2024-05-14 Issue: Volume: Page:
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Skiba Meredith A.,Sterling Sarah M.,Rawson Shaun^ORCID,Zhang Shuhao^ORCID,Xu Huixin,Jiang Haoran^ORCID,Nemeth Genevieve R.,Gilman Morgan S. A.,Hurley Joseph D.^ORCID,Shen Pengxiang^ORCID,Staus Dean P.,Kim Jihee,McMahon Conor,Lehtinen Maria K.,Rockman Howard A.^ORCID,Barth Patrick^ORCID,Wingler Laura M.^ORCID,Kruse Andrew C.^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Helen Hay Whitney Foundation

Howard Hughes Medical Institute

New York Stem Cell Foundation

Pew Charitable Trusts

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Ludwig Institute for Cancer Research

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41589-024-01620-6.pdf

Reference77 articles.

1. Mullard, A. 2022 FDA approvals. Nat. Rev. Drug Discov. 22, 83–88 (2023).

2. Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schioth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829–842 (2017).

3. Peterson, S. M. et al. Discovery and design of G protein-coupled receptor targeting antibodies. Expert Opin. Drug Discov. 18, 417–428 (2023).

4. Niwa, R. et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64, 2127–2133 (2004).

5. Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746 (2019).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carnosic acid, a novel food-source AT1R antagonist and its anti-hypertension mechanism;International Journal of Biological Macromolecules;2024-10

2. Nanobody pharmacology;Science Signaling;2024-05-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3